BTIG has adjusted its outlook on RxSight Inc. (NASDAQ: RXST), reducing the price target to $59 from the previous $73, while reiterating a Buy rating for the stock in view of RxSight's second-quarter financial results for the fiscal year 2024, which showcased a revenue of $34.9 million, marking a significant 67.6% year-over-year increase.
This figure surpassed both BTIG's and consensus estimates, which were set at $32.2 million and $32.3 million, respectively.
RxSight reported an adjusted loss per share (LPS) of $0.00, outperforming the anticipated adjusted LPS of $(0.20) and $(0.22). The company's performance was bolstered by the delivery of 78 Light Delivery Devices (LDDs), indicating growth of 16.4% year-over-year and 18.2% quarter-over-quarter. Additionally, the use of 24,214 Light Adjustable Lenses (LALs) represented a staggering 92.0% year-over-year and 19.8% quarter-over-quarter increase.
The company's utilization rate also saw impressive growth, reaching 11.0 LALs per LDD per month, a 19.5% rise year-over-year and an acceleration compared to the first and second quarters of the previous fiscal year, which saw a 5.2% quarter-over-quarter growth.
In response to these robust results, RxSight has raised its fiscal year 2024 guidance by $5 million at the midpoint, now forecasting revenues in the range of $139.0 million to $140.0 million, translating to a 56% to 57% year-over-year increase.
Despite a noted increase in operating expenses, the majority of this surge was attributed to non-cash based increases in stock-based compensation (SBC). BTIG's analysis suggests that the recent quarter's performance has eased concerns regarding RxSight's market position.
BTIG highlighted that RxSight's growing adoption rates, as evidenced by utilization metrics, are promising signs for investors.
The company's efforts to expand the applicability of its technology to a broader patient population are expected to create a positive feedback loop for physicians, both clinically and economically, by increasing the number of patients eligible for treatment with LDDs and LAL+.
InvestingPro Insights
As RxSight Inc. (NASDAQ:RXST) continues to navigate the competitive landscape, recent data from InvestingPro underscores the challenges and potential the company faces. With a market capitalization of $1.59 billion, RxSight is trading at a high Price / Book multiple of 9.7, which, despite the company's impressive revenue growth of 75.67% in the last twelve months as of Q1 2024, suggests a premium valuation. This is further complicated by the fact that analysts do not expect the company to be profitable this year, as indicated by the negative P/E ratios of -32.61 and adjusted -36.99. Moreover, the stock has experienced significant volatility, with a one-month price total return of -28.39%, reflecting investor uncertainty.
However, it's not all challenging news. The substantial revenue growth and a gross profit margin of 63.39% in the last twelve months point towards a robust underlying business model. Additionally, InvestingPro Tips indicate that the stock's RSI suggests it is in oversold territory, which could appeal to investors looking for a potential rebound. Furthermore, RxSight operates with a moderate level of debt and has liquid assets that exceed short-term obligations, providing some financial stability.
For investors seeking a deeper analysis, InvestingPro offers additional tips, including insights on the stock's performance over different time frames and fundamental analysis. There are 9 more InvestingPro Tips available for RxSight, which can be explored for a comprehensive investment strategy. These tips can be found at: https://www.investing.com/pro/RXST.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.